top of page

EHA 2026: Legend Biotech CEO Ying Huang discusses the company's late-breaking in vivo CAR-T presentation showing a 6/6 overall response and 5/6 complete response at the highest dose level in NHL

  • 4 hours ago
  • 1 min read

LB2501 is a CD19/CD20 dual targeting CAR-T. He discusses the EHA data, and next steps for the program. Plus, a review of last week's DLL3 data from ASCO and how he thinks about partnering and the competitive landscape.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page